Author

S. Chennuru

Observed name: Sudhathi Chennuru

Institutions: National Cancer Institute, Hematology Oncology Consultants

Observed institutions: Wright State University, Dayton VA Medical Center, National Cancer Institute, Hematology Oncology Consultants, Columbus Community Clinical Oncology Program

OpenAlex ID: A5037089797

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer

2016 · Z. A. Nahleh, W. E. Barlow, et al. · Breast Cancer Research and Treatment · 87

Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid

2008 · S. Chennuru, J. Koduri, et al. · Internal Medicine Journal · 64

Abstract P3-11-16: S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131)

2015 · Zeina A Nahleh, William E Barlow, et al. · Cancer Research · 13

Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin

2007 · S. Chennuru, M. A. Baumann · Internal Medicine Journal · 4

Works count: 4

Citation count: 168

H-index: 4

I10-index: 3